Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease ... Richard Pratley, MD is a paid Novo Nordisk, Inc. spokesperson.

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by China-based The United Laboratories International Holdings Limited.

Several hundred units of counterfeit Ozempic (semaglutide) injection 1 mg have been found in the United States. The FDA ...

Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus. A clinical trial ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial1.Data ...

Novo Nordisk already has broad FDA approvals ... 2 diabetes who also have atherosclerotic cardiovascular disease (ASCVD) or chronic kidney disease (CKD). It would become the first add-on ...

chronic kidney disease and those who are overweight or obese. It is also approved for similar trials in the U.S. The deal comes as Novo Nordisk works to expand its lineup of advanced weight-loss ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Globally, the rate of death from chronic kidney disease increased 24% from 1990 to 2021, according to statistics published by the American Heart Association, a global force changing the future ...